Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 16
Submit an article Journal homepage
127
Views
5
CrossRef citations to date
0
Altmetric
Reviews

A review on the treatment of relapsed/metastatic head and neck cancer

Daris Ferrari San Paolo Hospital, Department of Oncology, via Di Rudini 8, 20142, Milan, Italy +39 028 184 3159; +39 028 912 1690; [email protected]
,
Carla Codecà San Paolo Hospital, Department of Oncology, via Di Rudini 8, 20142, Milan, Italy +39 028 184 3159; +39 028 912 1690; [email protected]
,
Jessica Fiore San Paolo Hospital, Department of Oncology, via Di Rudini 8, 20142, Milan, Italy +39 028 184 3159; +39 028 912 1690; [email protected]
,
Andrea Luciani San Paolo Hospital, Department of Oncology, via Di Rudini 8, 20142, Milan, Italy +39 028 184 3159; +39 028 912 1690; [email protected]
&
Paolo Foa San Paolo Hospital, Department of Oncology, via Di Rudini 8, 20142, Milan, Italy +39 028 184 3159; +39 028 912 1690; [email protected]
Pages 2625-2632 | Published online: 27 Aug 2009

Bibliography

  • Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22:1743-52
  • Psyrri A, Fountzilas G. Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. Med Oncol 2006;23:1-15
  • Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
  • Tannock IF. Chemotherapy for head and neck cancer. J Otolaryngol 1984;13:99-104
  • Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit Rev Oncol Hematol 1984;1:323-55
  • Glick JH, Zehngebot LM, Taylor SG. Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. Am J Otolaryngol 1980;1:306-23
  • Amer MH, Al-Sarraf M, Vaitkevicius VK. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 1979;43:2202-6
  • de Graeff A, de Leeuw JR, Ros WJ, Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001;37:332-9
  • Penel N, Berthon C, Everard F, Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. Oral Oncol 2005;41:884-9
  • Johnson N. Tobacco use and oral cancer: a global perspective. J Dent Educ 2001;65:328-39
  • Rosenquist K. Risk factors in oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Swed Dent J 2005;179:1-66
  • Taylor SGt, McGuire WP, Hauck WW, A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 1984;2:1006-11
  • Woods RL, Fox RM, Tattersall MH. Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation. BMJ 1981;282:600-2
  • Pitman SW, Miller D, Weichselbaum R. Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue. Laryngoscope 1978;88:632-8
  • Carter SK, Slavik M. Current investigational drugs of interest in the chemotherapy program of the National Cancer Institute. Natl Cancer Inst Monogr 1977;45:101-21
  • Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol Clin North Am 1980;13:515-20
  • Eisenberger M, Hornedo J, Silva H, Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986;4:1506-9
  • Wittes R, Heller K, Randolph V, Cis-Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 1979;63:1533-8
  • Wittes RE, Cvitkovic E, Shah J, CISDichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:359-66
  • Grose WE, Lehane DE, Dixon DO, Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat Rep 1985;69:577-81
  • Forastiere AA, Metch B, Schuller DE, Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51
  • Jacobs C, Lyman G, Velez-Garcia E, A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63
  • Morton RP, Rugman F, Dorman EB, Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-9
  • Clavel M, Vermorken JB, Cognetti F, Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CARBO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-6
  • Catimel G, Verweij J, Mattijssen V, Docetaxel (Taxotere). An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck – EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-7
  • Dreyfuss AI, Clark JR, Norris CM, Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-8
  • Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005;17:218-24
  • Forastiere AA, Shank D, Neuberg D, Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-4
  • Smith RE, Thornton DE, Allen J. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies. Semin Oncol 1995;22:41-6
  • Langer CJ, Li Y, Jennings T, Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 2004;22:823-31
  • Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004;9(Suppl 2):3-8
  • Green MC, Buzdar AU, Smith T, Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-92
  • Sparano J, Wang M, Martino S, Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup TrialE1199. J Clin Oncol 2007;25(18 Suppl):516 (abstract)
  • Burstein HJ, Manola J, Younger J, Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-19
  • Guardiola E, Peyrade F, Chaigneau L, Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071-6
  • Gibson MK, Li Y, Murphy B, Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-7
  • Forastiere AA, Leong T, Rowinsky E, Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group study E1393. J Clin Oncol 2001;19:1088-95
  • Ferrari D, Fiore J, Codecà C, A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anticancer Drugs 2009;20:185-90
  • Shin DM, Glisson BS, Khuri FR, Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:1325-30
  • Shin DM, Khuri FR, Glisson BS, Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001;91:1316-23
  • Janinis J, Papadakou M, Xidakis E, Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000;23:128-31
  • Ang KK, Berkey BA, Tu X, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6
  • Lothaire P, de Azambuja E, Dequanter D, Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 2006;28:256-69
  • Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
  • Bernier J. Cetuximab in the treatment of head and neck cancer. Expert Rev Anticancer Ther 2006;6:1539-52
  • Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005;5:1085-93
  • Rocha-Lima CM, Soares HP, Raez LE, EGFR targeting of solid tumors. Cancer Control 2007;14:295-304
  • Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007;96:408-16
  • Vermorken JB, Trigo J, Hitt R, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7
  • Vermorken JB, Bourhis J, Trigo M, Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck refractory to first-line platinum-based therapies [abstract]. J Clin Oncol 2005;23(Suppl): abstract 5505
  • Burtness B, Goldwater MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54
  • Yang XD, Xiao-Chi J, Corvalan JRF, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer chemotherapy. Crit Rev Oncol Hematol 2001;38:17-23
  • Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002;29(Suppl 4):47-50
  • SPECTRUM: Study of Panitumumab Efficacy in Patients with Recurrent and/or Metastatic Head and Neck Cancer. National Cancer Institute website. Available from: www.clinicaltrials.gov.ct [Last accessed 7 May 2009]
  • Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007;96:408-16
  • Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82
  • Cohen EE, Rosen F, Stadler WM, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7
  • Wheeler RH, Jones D, Sharma P, Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. J Clin Oncol 2005;23:5531
  • Cohen EE, Kane MA, List MA, Phase II trial of gefitinib 250mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-24
  • Kirby AM, A'Hern RP, D'Ambrosio C, Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006;94:631-6
  • Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85
  • Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1864-71
  • Belon J, Irigoyen A, Rodriguez I, Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005;23(Suppl): abstract 5563
  • Kim ES, Kies M, Glisson BS, Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]. J Clin Oncol 2007;25(Suppl): abstract 6013
  • Abidoye OO, Cohen EE, Wong SJ, A phase II study of lapatinib (GW572016) in recurrent/metastatic squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol 2006;24(Suppl): abstract 5568
  • Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
  • Elser C, Siu LL, Winquist E, Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-73
  • Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80
  • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
  • Ferrara N, Hillan KJ, Gerber HP, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
  • Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
  • Miller KD, Chap LI, Holmes FA, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
  • Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
  • Rini BI, Halabi S, Rosenberg JE, Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8
  • O-charoenrat P, Rhys-Evans P, Modjtahedi H, Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000;18:155-61
  • Vokes EE, Cohen EE, Mauer AM, A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 2005;23:5504 (abstract)
  • Karamouzis MV, Friedland D, Johnson R, Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis [abstract]. J Clin Oncol 2007;25:6049
  • Chung CH, Ely K, McGavran L, Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6
  • Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2- activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19:634-40
  • Sok JC, Coppelli FM, Thomas SM, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-73
  • Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008;20:256-63
  • Langer CJ. Targeted therapy in head and neck cancer. State of the art 2007 and review of clinical applications. Cancer 2008;12:2635-45

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.